CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to OTSKF

Aripiprazole tablet, 10 mg

Phase 3
OTSUKA (OTSKF)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

9

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Schizophrenia

Clinical Trial

NCT00102063

Last updated: 9/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Aripiprazole Mylan

Treatment of schizophrenia, treatment and prevention of bipolar disorder (manic episodes).

View on EMA
EMAPending

Abilify MyCite

Treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence

View on EMA
EMAPending

Asimtufii

Maintenance treatment of schizophrenia.

View on EMA
EMAPending

Aripiprazole Mylan

Treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder

View on EMA
EMA11/15/2015

Aripiprazole Accord

Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

View on EMA
EMA8/20/2015

Aripiprazole Sandoz

Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

View on EMA
EMA6/30/2015

Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)

Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

View on EMA
EMA6/25/2015

Aripiprazole Zentiva

Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

View on EMA
EMA11/14/2013

Abilify Maintena

Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.